Our Company

Our Company

Corporate Responsibility

Leadership

Corporate Responsibility

Disclosures

Reconciliation Action Plan

Derived from the expression 'securing health for all of us', CSL Seqirus has public health protection at its core.
Learn more

At CSL Seqirus, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.
Learn more
Expertise

Expertise

Antivenoms and Q Fever Vaccines

In-licensing

Influenza

Iron Deficiency

Nephrology

Antivenoms and Q Fever Vaccines

Antivenom video

Australian Bites and Stings

Influenza

Pandemic Response Solutions

CSL Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.
Learn more

CSL Seqirus is on the front line of battling influenza, working hard to suppress costly and life-threatening epidemics and pandemics. Vaccination is the most effective way to prevent influenza .
Learn more
R&D

R&D

Research Practices

Investigator Initiated Studies

Our CSL Seqirus research and development group provides support to ensure the conditions are optimised for efficient vaccine manufacture. Activities also focus on improving the effectiveness of current influenza vaccines and their manufacturing processes.
Learn more

At CSL Seqirus, we are committed to carrying out R&D in an ethical and transparent way as well as in accordance with government regulations and industry codes for good practice.
Learn more
Manufacturing

Manufacturing

Global Manufacturing Network

Technologies

Technical Development

Quality & Safety

New Facility - Suppliers

One of the largest influenza vaccine companies in the world, CSL Seqirus operates state-of-the-art manufacturing facilities in three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world.
Learn more

CSL Seqirus utilises both egg and cell-based production technologies and we offer a broadest portfolio of influenza vaccines. We have commercialised the only adjuvanted seasonal influenza vaccine for older adults and paediatrics and offer two different types of quadrivalent influenza vaccines.
Learn more
Products
Careers

Careers

Graduate Program

See Yourself at CSL Seqirus

Discover Our People

Diversity and Inclusion

How we care for you at CSL Seqirus

When you join CSL Seqirus, you join a team dedicated to protecting people and communities from influenza. It's a feeling of purpose and possibility that inspires us every day.
Learn more

It doesn't matter whether you are a scientist or an administrator, a marketer or an operator - as long as you are inspired by the chance to create something that will help others, you can find your role at CSL Seqirus.
Learn more

Jonathan Edelman

Senior Vice President, Vaccines Innovation Unit (VIU)

Dr. Jonathan Edelman is Senior Vice President, Vaccines Innovation Unit (VIU). In this role, Jon oversees research, clinical development, and program leadership related to vaccines, including the existing CSL Seqirus product portfolio and future vaccine innovations. Prior to his appointment, Jon was the Vice President of Clinical Development at CSL Seqirus, responsible for the company’s clinical research on a wide portfolio of influenza vaccines.

Jon has more than 27 years of experience in the pharmaceutical industry. He received his bachelor degree in 1979 from Princeton University and his medical degree from the Mt. Sinai School of Medicine in 1983.